Device Trial Radar · NCT03243734
trūFreeze® Palliative Esophageal Cancer
Last checked: Nov 19, 2026Latest source record: May 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Nov 6, 2017
Primary completion
Jul 13, 2022
Study completion Mar 6, 2024
Sponsor
- Lead sponsor
- US Endoscopy Group Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 9, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective, open label, non-controlled single arm, multi-center study The primary objective is to study the effects of the trūFreeze® Spray Cryotherapy System in a population of subjects who have been diagnosed with persistent local esophageal cancer and who are not surgical candidates or have completed or declined systemic therapy.
Conditions
- Esophageal Cancer
Interventions
trūFreeze® System spray cryotherapyDevice
Subjects where trūFreeze® System spray cryotherapy is performed
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline EORTC at 14 days post cryotherapy procedureTime frame: 14 days post spray cryotherapy
- Change from baseline dysphagia scale at 14 days post cryotherapy procedureTime frame: 14 days post spray cryotherapy
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Cancer Treatment Centers of America Western Regional Medical Center
Goodyear, Arizona
University of California at Irvine
Orange, California
Emory University
Atlanta, Georgia
7 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.